Perceptive Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$104M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$59.7M |
| 3 |
Zymeworks
ZYME
|
+$47.4M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$39.5M |
| 5 |
Black Diamond Therapeutics
BDTX
|
+$33.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$152M |
| 2 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$78.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$53.8M |
| 4 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
+$37.3M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$23.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.4% |
| 2 | Financials | 0.28% |
| 3 | Technology | 0.27% |
| 4 | Consumer Discretionary | 0.02% |
Similar funds
Perceptive Advisors's Q1 2020 Portfolio in Review
As of Q1 2020, Perceptive Advisors held 140 positions worth $3.84B, down 24% from $5.03B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Perceptive Advisors deployed $214M of net new capital in Q1 2020, opening 25 new positions and adding to 22 existing holdings. Its largest new stake was Gilead Sciences: 1,500,000 shares worth $11.2M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $78.1M trimmed.
- Perceptive Advisors's largest Q1 2020 buy was Gilead Sciences: 1,500,000 shares worth $11.2M.
- Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2020, an estimated $59.7M increase.
- Perceptive Advisors's biggest Q1 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $78.1M.
- Perceptive Advisors fully exited Amarin Corp in Q1 2020, selling an estimated $152M.
- Perceptive Advisors's ten largest holdings make up 55% of its $3.84B portfolio in Q1 2020.
- Perceptive Advisors opened 25 new positions and closed 27 in Q1 2020.
- Perceptive Advisors's portfolio value fell 24% quarter-over-quarter to $3.84B.
Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.